Clinical Trial Protocol
Iranian Registry of Clinical Trials

17 Sep 2026

Comparative bioequivalence study of the 10-mg Fampridine Tablets manufactured by Zahravi Pharmaceutical Company

Protocol summary

Study aim

Demonstration of bioequivalence of Fampridine 10-mg Tablet of Zahravi Pharmaceutical Company with Fampyra® Tablet manufactured by Biogen Idec company after single dose administration.

Design

Single dose, randomized and crossover bioequivalence study of Fampridine 10-mg tablet by Zahravi Co. with Fampyra® (Biogen Idec Co.) in 24 healthy male volunteers in two groups under fasting condition.

Settings and conduct

Study place and the place for Blood sample analysis are the Drug Applied Research Center affiliated to Tabriz University of Medical Science, respectively. 24 healthy male volunteers will receive each of test or reference Fampridine 10-mg Tablet in random sequence according to the randomization schedule. The interval between receiving the medicine (washout period) is 7 days, If the first sequence receives Iranian medicine, they will receive brand medicine. Blood samples will be taken from all participants before and after receiving the drug at 1، 1.5، 2، 2.5، 3، 3.5، 4، 4.5، 5 ، 5.5، 6، 8 ، 10 ، 12 and 24 hours after dosing.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Healthy male subjects in the age range of 18-50 years and BMI (Body Mass Index) of 18.5-30. Exclusion criteria: Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function or a history of TB, epilepsy, asthma, DM, psychosis or glaucoma and regular smoker.

Intervention groups

Intervention group 1: Fampridine 10-mg Tablet by Zahravi Co. is the test product. Intervention group 2: Fampyra® (Biogen Idec Co.) is the reference product. In each period, 12 of 24 subjects will be given single dose of this product.

Main outcome variables

Peak Plasma Concentration (Cmax); Area under the concentration-time curve (AUC).

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200407046981N23**
Registration date: **2022-01-22, 1400/11/02**
Registration timing: **prospective**

Last update: **2022-01-22, 1400/11/02**
Update count: **0**

Registration date

2022-01-22, 1400/11/02

Registrant information

Name

Fatima Molavi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3336 2700

Email address

molavif@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-04-08, 1401/01/19

Expected recruitment end date

2022-06-09, 1401/03/19

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title
Comparative bioequivalence study of the 10-mg Fampridine Tablets manufactured by Zahravi Pharmaceutical Company

Public title
Study of absorption and elimination rate of Fampridine 10-mg tablet in comparison with Fampridine brand tablet (Fampyra®).

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:
The weight limit of each volunteer should be between 60 and 100 kg. All volunteers must be non-smokers. They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed. Candidates who have consented to the consent form.

Exclusion criteria:
Known hypersensitivity or idiosyncratic reaction to Fampridine or any ingredients. Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg. Regular smoker who smokes more than ten cigarettes daily. Taking any medicine during two weeks before dosing.

Age
From **18 years** old to **55 years** old

Gender
Male

Phase
Bioequivalence

Groups that have been masked
No information

Sample size
Target sample size: **24**

Randomization (investigator's opinion)
Randomized

Randomization description
To randomly assign people in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope after entering the study, and numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of the both groups will change for the second period.

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics committee of Tabriz University of Medical Science

Street address
Third floor, central building No. 2, Golgasht street, Tabriz University of Medical Science, Tabriz, Iran

City
Tabriz

Province
East Azarbaijan

Postal code
5166614766

Approval date
2021-11-28, 1400/09/07

Ethics committee reference number
IR.TBZMED.REC.1400.812

Health conditions studied

1

Description of health condition studied
Bioequivalence study

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description
Peak Plasma Concentration (Cmax)

Timepoint
At 0 before dosing, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12 and 24 hours after dosing

Method of measurement
High-performance liquid chromatography—mass spectrometry (HPLC-MS)

Secondary outcomes

1

Description
AUC (Area Under the Concentration-Time Curve)

Timepoint
At 0 before dosing, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12 and 24 hours after dosing

Method of measurement
Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSS

Intervention groups

1

Description
Intervention group 1: In this group, volunteers are given a single oral dose of Fampridine 10-mg tablet produced by Zahravi Co. (Domestic). In each period, 12 of 24 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

2

Description
Intervention group 2: In this group, volunteers are given a single oral dose of Fampridine 10-mg tablet (Fampyra), produced by Biogen Idec Company (Brand). In each period, 12 of 24 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Drug Applied Research Center
Full name of responsible person
Dr Hamed Hamishehkar
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Fax
+98 41 3336 7914
Email
hamishehkar.hamed@gmail.com
Web page address
https://darc.tbzmed.ac.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Zahravi pharmaceutical company
Full name of responsible person
Hussein Eslami
Street address
No. 23, Entrance No. 2, Darupakhsh Factories, Daropakhsh St., Karaj (Lashgari) Special Road, 18th Corner, Tehran
City
Tehran
Province
Tehran
Postal code
1397116396
Phone
+98 21 4499 1893
Fax
+98 21 4499 4315
Email
CEO@zahravipharma.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Zahravi pharmaceutical company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaeutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Email
Hamishehkar.hamed@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person
Jaber Emami

Position
Professor

Latest degree
Ph.D.

Other areas of specialty/work
Pharmaceutics

Street address
Hezarjarib St., School of Pharmacy and Pharmaceutical Sciences , Isfahan, Iran

City
Isfehan

Province
Isfehan

Postal code
8174673461

Phone
+98 31 3792 7111

Fax
+98 31 3668 0011

Email
Emami@pharm.mui.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Fatima Molavi

Position
Non-faculty academic specialist

Latest degree
Ph.D.

Other areas of specialty/work
Pharmaceutics

Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran

City
Tabriz

Province
East Azarbaijan

Postal code
5165665811

Phone
+98 41 3336 7914

Email
F.molavi85@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD
There is no further information

Study Protocol
Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan
No - There is not a plan to make this available

Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available

Analytic Code
Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary
No - There is not a plan to make this available